We have updated our MRI Screening Form recently in response to a public health advisory issued by the FDA in December 2006. The update is entitled "Update on Magnetic Resonance Imaging (MRI) Contrast Agents Containing Gadolinium and Nephrogenic Fibrosing Dermopathy". The FDA is currently studying a potential connection between certain patients who've received an MRI scan with Gadolinium and the potential to develop Nephrogenic Systemic Fibrosis or Nephrogenic Fibrosing Dermopathy (NSF/NFD). NSF/NFD may occur in patients with moderate to end-stage kidney disease after they have had an MRI or MRA scan with a Gadolinium-based contrast agent.We have also updated our policy regarding Gadolinium Contrast Administration and are carefully screening patients for any moderate to end-stage renal disease. It's important to note that in most cases of patients who have developed NSF/NFD, the patients had been given more than 0.1mmol/kg of Gadolinium; we only give above this amount for approximately 1% of our Gadolinium procedures.
For more information about MRI at PIC, click here to see our MRI Services page.